Jianfeng Group Pro 2015-003 (Announcement on Resolution of 2nd Board of Supervisors of Jianfeng Group's 8th Session)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-003
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on the Resolution of the Second Meeting of the Eighth Board of Supervisors
The Board of Supervisors and all supervisors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Meeting of the 1. Board of Supervisors
(I) The convening and convening of this meeting of the Board of Supervisors complies with relevant laws, regulations and the relevant provisions of the Company's Articles of Association.
(II) on April 3, 2015, the company issued the notice of the meeting of the board of supervisors by fax, e-mail and personal service.
(III) 2015 4 1 7, this board of supervisors meeting was held in the conference room on the third floor of Jianfeng Building, Jinhua City, Zhejiang Province by on-site voting.
(IV) 5 supervisors who should attend the meeting of the board of supervisors, 5 supervisors who actually attended the meeting, and 5 valid votes for the meeting.
(V) This board of supervisors is presided over by Mr. Li Ziqiang, chairman of the board of supervisors.
2. the review of the board of supervisors meeting
, approved the company's 2014 annual report and its summary
the board of supervisors carefully reviewed the 2014 annual report and its summary, and held that:
( 1 ) annual report preparation and review procedures comply with laws, regulations, articles of association and the company's internal management system;
(2) The content and format of the annual report comply with the regulations of the China Securities Regulatory Commission and the stock exchange, the information contained truly reflects the company's management and financial status in 2014 from all aspects.
(3) No issue The personnel who participated in the preparation and review of the annual report have violated the confidentiality provisions .
voting result: 5 votes in favor, 0 votes against, 0 abstention
This proposal needs to be submitted to the shareholders' meeting for deliberation.
2, passed the 2014 financial final accounts report
meeting after deliberation and voting, passed the bill.
Voting Result: 5 votes in favor, 0 votes against, 0 abstention
This proposal needs to be submitted to the shareholders' meeting for deliberation.
, passed the 2014 work report of the board of supervisors of the company
. the meeting held that the report fully reflects the work of the board of supervisors of the company in 2014, and this proposal needs to be submitted to the shareholders' meeting for deliberation.
voting results: 5 votes in favor, 0 votes against, 0 abstentions
4, passed the 2014 internal control evaluation report
meeting after deliberation and voting, passed the bill.
voting results: 5 votes in favor, 0 votes against, 0 abstentions
5, passed the daily related party transaction motion
meeting after deliberation and voting, passed the motion.
voting results: 5 votes in favor, 0 votes against, 0 abstention
6, passed 's proposal on authorizing the chairman of the company to use idle own funds to entrust financial management and other investment
meeting passed the proposal after deliberation and voting.
voting results: 5 votes in favor, 0 votes against, 0 abstentions
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Supervisory Board
April 21, 2015
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page